ANI PHARMACEUTICALS INC

ANI PHARMACEUTICALS INC (ANIP) is a publicly listed company on US equity markets.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

The company reports trailing twelve-month revenue of $49.77M and net income of $29.49M.

Key metrics include a return on equity of 5.2%, a debt-to-equity ratio of 1.53.

Use FINOTAUR to track ANIP's price action, review fundamentals, and stay current with company news — all in one research dashboard.